BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

29 related articles for article (PubMed ID: 26916894)

  • 21. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
    Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P
    Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of MDM2 single nucleotide polymorphism on tumor onset in head and neck squamous cell carcinoma.
    Nakashima M; Kondo S; Shimizu Y; Wakisaka N; Murono S; Furukawa M; Yoshizaki T
    Acta Otolaryngol; 2008 Jul; 128(7):808-13. PubMed ID: 18568525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation.
    Tu HF; Chen HW; Kao SY; Lin SC; Liu CJ; Chang KW
    Radiother Oncol; 2008 May; 87(2):243-52. PubMed ID: 18423915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck.
    Yu H; Huang YJ; Liu Z; Wang LE; Li G; Sturgis EM; Johnson DG; Wei Q
    Mol Carcinog; 2011 Sep; 50(9):697-706. PubMed ID: 21656578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation of TP53 and MDM2 genotypes and clinical outcome in platinum-treated head and neck cancer patients with more than 10 years' follow-up.
    Vivenza D; Monteverde M; Lattanzio L; Tonissi F; Astesana V; Denaro N; Comino A; Russi E; Lo Nigro C; Merlano M
    Int J Biol Markers; 2016 May; 31(2):e183-92. PubMed ID: 26916894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response.
    Zhou G; Liu Z; Myers JN
    J Cell Biochem; 2016 Dec; 117(12):2682-2692. PubMed ID: 27166782
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TP53 is not a prognostic marker-clinical consequences of a generally disregarded fact.
    Braunschmid T; Kührer I; Mittlböck M; Westerhoff M; Kappel-Latif S; Brammen L; Krishnadath KK; Phillips WA; Gnant M; Kandioler D
    Ann N Y Acad Sci; 2018 Dec; 1434(1):46-53. PubMed ID: 30112858
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 29.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.